Biocoryl
Biocoryl Uses, Dosage, Side Effects, Food Interaction and all others data.
A derivative of procaine with less CNS action.
Biocoryl is an agent indicated for production of local or regional anesthesia and in the treatment of ventricular tachycardia occurring during cardiac manipulation, such as surgery or catheterization, or which may occur during acute myocardial infarction, digitalis toxicity, or other cardiac diseases. The mode of action of the antiarrhythmic effect of Biocoryl appears to be similar to that of procaine and quinidine. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole. The sinoatrial node is, however, unaffected.
Trade Name | Biocoryl |
Availability | Prescription only |
Generic | Procainamide |
Procainamide Other Names | Procainamida, Procainamide, Procaïnamide, Procainamidum |
Related Drugs | propranolol, amiodarone, lidocaine, verapamil, Inderal, dofetilide |
Type | |
Formula | C13H21N3O |
Weight | Average: 235.3253 Monoisotopic: 235.168462309 |
Protein binding | 15 to 20% |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Biocoryl is a medication used to treat life threatening ventricular arrhythmias.
For the treatment of life-threatening ventricular arrhythmias.
Biocoryl is also used to associated treatment for these conditions: Supraventricular Arrhythmias, Ventricular Tachycardia (VT), Life-threatening ventricular arrhythmias, Pre-excited atrial fibrillation
How Biocoryl works
Biocoryl is sodium channel blocker. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
Toxicity
LD50=95 mg/kg (rat, IV); LD50=312 mg/kg (mouse, oral); LD50=103 mg/kg (mouse, IV); LD50=250 mg/kg (rabbit, IV)
Food Interaction
- Avoid alcohol.
- Take with food. Food reduces irritation.
Biocoryl Alcohol interaction
[Minor] Ethanol may increase the acetylation of procainamide.
Subtherapeutic plasma levels of procainamide may result in some patients.
Because the acetylated metabolite of procainamide also possesses antiarrhythmic properties, the clinical effects are unclear.
Biocoryl Drug Interaction
Major: haloperidol, levofloxacinModerate: ipratropium, olanzapineUnknown: aspirin, etomidate, lorazepam, diltiazem, docusate, warfarin, rosuvastatin, glucose, phenytoin, apixaban, clonazepam, furosemide, atorvastatin, enoxaparin, clopidogrel, ketorolac
Volume of Distribution
- 2 L/kg
Elimination Route
75 to 95%
Half Life
~2.5-4.5 hours
Elimination Route
Trace amounts may be excreted in the urine as free and conjugated p-aminobenzoic acid, 30 to 60 percent as unchanged PA, and 6 to 52 percent as the NAPA derivative.
Innovators Monograph
You find simplified version here Biocoryl